Toll Free: 1-888-928-9744

Febrile Neutropenia - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Febrile Neutropenia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape.

Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of chemotherapy when it is myelosuppressive (suppresses the bone marrow from producing blood cells). Symptoms include fever, flu-like symptoms, shaking chills, severe night sweats, nausea and vomiting, especially with fever, tenderness, redness, swelling, pain or discharge at the site of a catheter and headache or neck stiffness. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Febrile Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Febrile Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 1, 2, 2, 1 and 3 respectively for Febrile Neutropenia.

Febrile Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Febrile Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Febrile Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Febrile Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Febrile Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Febrile Neutropenia (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Febrile Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Febrile Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Febrile Neutropenia Overview 7 Therapeutics Development 8 Pipeline Products for Febrile Neutropenia - Overview 8 Febrile Neutropenia - Therapeutics under Development by Companies 9 Febrile Neutropenia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Febrile Neutropenia - Products under Development by Companies 15 Febrile Neutropenia - Companies Involved in Therapeutics Development 16 Apotex Inc. 16 BeyondSpring Pharmaceuticals, Inc. 17 Biogenomics Limited 18 Coherus BioSciences, Inc. 19 Dr. Reddy's Laboratories Limited 20 Richter Gedeon Nyrt. 21 Sandoz International GmbH 22 Therapeutic Proteins International, LLC 23 USV Pvt Ltd 24 Febrile Neutropenia - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 EC-18 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 filgrastim - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 filgrastim - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 filgrastim - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 pegfilgrastim - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 pegfilgrastim - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 pegfilgrastim - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 pegfilgrastim - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 pegfilgrastim - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 pegfilgrastim - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 pegfilgrastim - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 pegfilgrastim - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 pegfilgrastim - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 pegfilgrastim - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 plinabulin - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Febrile Neutropenia - Dormant Projects 53 Febrile Neutropenia - Product Development Milestones 54 Featured News & Press Releases 54 Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study 54 Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 55 Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 55 Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 56 Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program 56 Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim 57 Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 57 Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Febrile Neutropenia, H2 2016 8 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Febrile Neutropenia - Pipeline by Apotex Inc., H2 2016 16 Febrile Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016 17 Febrile Neutropenia - Pipeline by Biogenomics Limited, H2 2016 18 Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016 19 Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 20 Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016 21 Febrile Neutropenia - Pipeline by Sandoz International GmbH, H2 2016 22 Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016 23 Febrile Neutropenia - Pipeline by USV Pvt Ltd, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Febrile Neutropenia - Dormant Projects, H2 2016 53



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify